AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3.8 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access | Just Accepted

Advances in targeted delivery and combination immunotherapy of oncolytic viruses for glioma

Yuxuan Liu1,2,3, Yuejia Ding1, Jianshuang Chen2, Yi Xiao1, Jialei Wu1, Yunzhao Chen4( ), Yangyang Li5( ), Shibing Wang6,7( ), Xiaozhou Mou2,3 ( )

1 School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China

2 Center for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Clinical Research Institute, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou 310014, China

3 Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou 310014, China

4 Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China

5 Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310029, China

6 Department of Laboratory Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China

7 Zhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, China

Show Author Information

Abstract

Glioblastoma (GBM), as the most lethal malignancy of the central nervous system, faces the dual constraints of the physical barrier of the blood-brain barrier (BBB) and a highly immunosuppressive microenvironment, rendering conventional immunotherapies largely ineffective. Oncolytic viruses (OVs), which possess a dual capacity for selective tumor cell lysis and antitumor immunity induction, hold considerable promise for glioma treatment. Nevertheless, the clinical application of OVs remains severely constrained. The constraints include poor intracranial delivery efficiency, swift sequestration by the reticuloendothelial system, and the dampening of therapeutic outcomes. These outcomes are elicited by counter‑regulatory immunosuppressive signals that exist in the microenvironment. This review systematically examines diversified delivery strategies to address delivery challenges. The review also discusses the advantages and limitations of each strategy. Recognizing the suboptimal outcomes associated with single-agent regimens, we further delineate the synergistic interactions across multiple dimensions within combinatorial therapeutic approaches, thus establishing a robust theoretical foundation and proposing practical strategies for clinical translation of OVs-mediated immunotherapy for gliomas. Finally, this review envisions future directions, including personalized combination strategies, safety management, biomarker development, and manufacturing considerations, to inform precision immunotherapy for glioma.

Graphical Abstract

References

【1】
【1】
 
 
Nano Research

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Liu Y, Ding Y, Chen J, et al. Advances in targeted delivery and combination immunotherapy of oncolytic viruses for glioma. Nano Research, 2026, https://doi.org/10.26599/NR.2026.94909257

196

Views

9

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 02 September 2026
Revised: 09 October 2026
Accepted: 12 October 2026
Available online: 12 October 2026

© The Author(s) 2026. Published by Tsinghua University Press.

This is an open access article under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/)